Benitec Biopharma said this week that it has non-exclusively licensed its expressed RNAi technology to Calimmune for use in developing an RNAi-based HIV/AIDS treatment.
The deal covers the use of Benitec's technology against up to three viral and cellular genes identified as having therapeutic potential against HIV, Benitec said.
Additional terms of the deal were not disclosed.